CEFTAZIDIME, AVIBACTAM (AVYCAZ) Nursing Considerations

What is the generic name?

CEFTAZIDIME, AVIBACTAM

What is the Trade Name for CEFTAZIDIME, AVIBACTAM?

AVYCAZ

What are the Indications for CEFTAZIDIME, AVIBACTAM?

• 1 INDICATIONS AND USAGE AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients 3 months and older ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in adult and pediatric patients 3 months and older ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) in patients 18 years and older ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) 1. 1 Complicated Intra- a bdominal Infections (cIAI) AVYCAZ (ceftazidime and avibactam) in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients 3 months or older caused by the following susceptible Gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Enterobacter cloacae , Klebsiella oxytoca , Citrobacter freundii complex , and Pseudomonas aeruginosa . 1. 2 Complicated Urinary Tract Infections (cUTI), including Pyelonephritis AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric patients 3 months or older caused by the following susceptible Gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Citrobacter freundii complex , Proteus mirabilis , and Pseudomonas aeruginosa . 1.3 Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years or older caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae , Enterobacter cloacae , Escherichia coli , Serratia marcescens , Proteus mirabilis , Pseudomonas aeruginosa , and Haemophilus influenzae . 1. 4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy .

References: https://open.fda.gov/